The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1533
Lesinurad/Allopurinol (Duzallo) for Gout-Associated Hyperuricemia
The full article is available to subscribers Subscriber Login   

The FDA has approved Duzallo (Ironwood), a fixed-dose combination of the uric acid transporter 1 (URAT1) inhibitor lesinurad (Zurampic)1 and the xanthine oxidase inhibitor allopurinol (Zyloprim, and generics), for once-daily treatment of gout-associated hyperuricemia in patients who have not achieved target serum uric acid levels with allopurinol alone.

STANDARD TREATMENT — Recent guidelines offer conflicting views on the benefits of monitoring serum uric acid levels and the appropriate use of urate-lowering therapy in patients with gout,2-4 but most expert clinicians still treat gout-associated hyperuricemia initially with a xanthine oxidase inhibitor such as allopurinol or febuxostat (Uloric) with the goal of reducing the serum uric acid level to <6.0 mg/dL (and preferably to <5.0 mg/dL). The ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Lesinurad/Allopurinol (Duzallo) for Gout-Associated Hyperuricemia
Article code: 1533c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian